Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06710262 · ClinicalTrials.gov registry record

T-TAS® wS Method Comparison

A clinical trial of Von Willebrand Disease (VWD) and Healthy Donors, sponsored by Hikari Dx.

Completed
Registry status
115
Enrollment target
2
Study locations

NCT06710262 is a study of Von Willebrand Disease (VWD) and Healthy Donors that has completed, run by Hikari Dx. The registered enrollment target is 115 participants, above the 81-participant average among 4 other Von Willebrand Disease (VWD) trials with a reported enrollment target (42% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06710262, a study of Von Willebrand Disease (VWD) and Healthy Donors, has completed, sponsored by Hikari Dx.

COMPLETED
Registry status
115 participants
Enrollment target
2
Study locations

Study Summary

This study involves the collection of blood samples and measurement with the T-TAS PL assay to compare the performance of the T-TAS wS instrument to the T-TAS 01 instrument

Interventions

  • DIAGNOSTIC_TEST T-TAS PL Assay

Study Locations (2)

Florida

  • University of Florida Health Jacksonville - Jacksonville

Maryland

  • Sinai Hospital of Baltimore - Baltimore

Trial Details

FieldValue
Enrollment Target 115 participants
Start Date 2024-08-21
Est. Completion 2025-07-14

Sponsor

Hikari Dx

4 total trials

What the Registry Record Tells You About NCT06710262

The ClinicalTrials.gov registry entry for NCT06710262 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 81-participant average among 4 other Von Willebrand Disease (VWD) trials with a reported enrollment target (42% higher). The listed sponsor is Hikari Dx, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Von Willebrand Disease (VWD) appearing as the primary indexed condition, and to 1 intervention - of which T-TAS PL Assay is the first listed.

NCT06710262 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT06710262 about?

NCT06710262 is a clinical study titled "T-TAS® wS Method Comparison". This study involves the collection of blood samples and measurement with the T-TAS PL assay to compare the performance of the T-TAS wS instrument to the T-TAS 01 instrument

What is the current status of trial NCT06710262?

This trial is currently completed. The enrollment target is 115 participants. The study started on 2024-08-21. Estimated completion is 2025-07-14.

What conditions does trial NCT06710262 study?

This clinical trial studies the following conditions: Von Willebrand Disease (VWD), Healthy Donors, Antiplatelet Therapy.

What interventions are being tested in trial NCT06710262?

The interventions under investigation include: T-TAS PL Assay (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06710262?

This trial is sponsored by Hikari Dx, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06710262 being conducted?

This trial has 2 study locations across Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Von Willebrand Disease (VWD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.